Clukers, J. http://orcid.org/0000-0003-0021-8870
Lanclus, M.
Mignot, B.
Van Holsbeke, C.
Roseman, J.
Porter, S.
Gorina, E.
Kouchakji, E.
Lipson, K. E.
De Backer, W.
De Backer, J.
Article History
Received: 5 September 2018
Accepted: 21 October 2018
First Online: 6 November 2018
Ethics approval and consent to participate
: The original study was performed in accordance with the Declaration of Helsinki. Ethics committees at each participating institution reviewed and approved the protocol before subjects were enrolled in the trial. Each subject was fully informed of the risks and benefits of participating in this trial, and provided written informed consent prior to screening (ExternalRef removed number NCT01262001).
: Not applicable.
: - Dr. J. Clukers has nothing to disclose.- Dr. M. Lanclus has nothing to disclose.- Dr. B. Mignot reports personal fees from FLUIDDA nv, outside the submitted work.- Dr. C. Van Holsbeke reports personal fees from FLUIDDA nv, outside the submitted work.- Dr. J. Roseman has nothing to disclose.- Dr. S. Porter reports personal fees from FibroGen, Inc., during the conduct of the study; personal fees from FibroGen, Inc., outside the submitted work. Dr. Porter has a pending patent US. 9,480,449 issued to FibroGen, Inc.- Dr. E. Gorina reports personal fees from FibroGen, Inc., during the conduct of the study; personal fees from FibroGen, Inc., outside the submitted work.- Dr. E. Kouchakji reports other from FibroGen, Inc., outside the submitted work.- Dr. K. E. Lipson reports personal fees and other from FibroGen, Inc., outside the submitted work; In addition, Dr. Lipson has a patent US 9,587,016 issued to FibroGen, Inc.- Dr. W. De Backer has nothing to disclose.- Dr. J. De Backer reports to be founder and CEO of FLUIDDA nv, a company that actively develops and markets part of the technology described in this paper.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.